These findings underscore the protective role of the USP13-GRP78 axis in IBD and suggest that targeting USP13 through intestinal epithelial-specific gene therapy may be a potential therapeutic strategy for IBD. The gene discussed is USP13; the disease is inflammatory bowel disease.